JP2009532399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009532399A5 JP2009532399A5 JP2009503466A JP2009503466A JP2009532399A5 JP 2009532399 A5 JP2009532399 A5 JP 2009532399A5 JP 2009503466 A JP2009503466 A JP 2009503466A JP 2009503466 A JP2009503466 A JP 2009503466A JP 2009532399 A5 JP2009532399 A5 JP 2009532399A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- antibody
- treatment
- doc
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006015341A DE102006015341A1 (de) | 2006-04-03 | 2006-04-03 | Behandlung von multipler Sklerose und/oder rheumatoider Arthritis |
| PCT/EP2007/002929 WO2007115713A1 (de) | 2006-04-03 | 2007-04-02 | Behandlung von multipler sklerose und/oder rheumatoider arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009532399A JP2009532399A (ja) | 2009-09-10 |
| JP2009532399A5 true JP2009532399A5 (enExample) | 2012-12-13 |
Family
ID=38226352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503466A Pending JP2009532399A (ja) | 2006-04-03 | 2007-04-02 | 多発性硬化症および／または関節リウマチの処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9068002B2 (enExample) |
| EP (2) | EP2481757A1 (enExample) |
| JP (1) | JP2009532399A (enExample) |
| CN (1) | CN101466735A (enExample) |
| AU (1) | AU2007236269B2 (enExample) |
| CA (1) | CA2648330C (enExample) |
| DE (1) | DE102006015341A1 (enExample) |
| WO (1) | WO2007115713A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013276994C1 (en) * | 2007-08-13 | 2016-08-11 | Takeda Pharmaceutical Company Limited | IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease |
| EP2727944A1 (en) * | 2012-10-30 | 2014-05-07 | Universitätsklinikum Regensburg | Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system |
| EP3612563A1 (en) * | 2017-04-19 | 2020-02-26 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| WO2020232127A1 (en) * | 2019-05-13 | 2020-11-19 | The Research Foundation For The State University Of New York | Compositions and methods to block and bind ccr2 to modulate cellular function |
| JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
| WO2023072916A1 (en) | 2021-10-27 | 2023-05-04 | Granite Bio Ag | Antibodies targeting ccr2 |
| CN121399160A (zh) | 2023-05-29 | 2026-01-23 | 花岗岩生物股份公司 | 靶向ccr2的抗体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE9600820D0 (sv) | 1996-03-01 | 1996-03-01 | Pharmacia Ab | Antibodies and their use |
| US6696550B2 (en) * | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| US6723538B2 (en) * | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| AU2001233277B2 (en) | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| SE0002045D0 (sv) | 2000-05-31 | 2000-05-31 | Sahltech Ab | New use |
| US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
| WO2005060368A2 (en) * | 2003-12-10 | 2005-07-07 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use |
-
2006
- 2006-04-03 DE DE102006015341A patent/DE102006015341A1/de not_active Withdrawn
-
2007
- 2007-04-02 JP JP2009503466A patent/JP2009532399A/ja active Pending
- 2007-04-02 US US12/295,718 patent/US9068002B2/en active Active
- 2007-04-02 EP EP12165439A patent/EP2481757A1/de not_active Withdrawn
- 2007-04-02 CA CA2648330A patent/CA2648330C/en not_active Expired - Fee Related
- 2007-04-02 AU AU2007236269A patent/AU2007236269B2/en not_active Ceased
- 2007-04-02 WO PCT/EP2007/002929 patent/WO2007115713A1/de not_active Ceased
- 2007-04-02 CN CNA2007800203076A patent/CN101466735A/zh active Pending
- 2007-04-02 EP EP07723870.7A patent/EP2004692B1/de active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI784988B (zh) | 治療發炎症狀的方法 | |
| Van Vollenhoven et al. | Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo‐controlled trial | |
| CN111939261B (zh) | 以il-4r抑制剂治疗嗜酸性食管炎的方法 | |
| Miller et al. | The pharmacokinetics of d-tubocurarine in man with and without renal failure. | |
| Grando | New approaches to the treatment of pemphigus | |
| JPH07504888A (ja) | ＣＤｗ５２−多発性硬化症の治療のための特異抗体 | |
| RU2607022C2 (ru) | Способы и композиции для лечения волчанки | |
| TW202038999A (zh) | 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 | |
| JP2021532057A (ja) | 代謝機能不全または低レプチン血症の治療に使用するためのレプチン受容体アゴニスト性抗体 | |
| CN113574071B (zh) | 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物 | |
| Takeuchi et al. | Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate | |
| Gonzalo et al. | Differential in vivo effects of a superantigen and an antibody targeted to the same T cell receptor. Activation-induced cell death vs passive macrophage-dependent deletion. | |
| HK1213782A1 (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| Füchtenbusch et al. | Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens. | |
| CN101466735A (zh) | 多发性硬化和/或类风湿性关节炎的治疗 | |
| Matsumoto et al. | Different roles of interleukin‐10 in onset and resolution of asthmatic responses in allergen‐challenged mice | |
| Takae et al. | Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies | |
| WO2024152001A1 (en) | Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome | |
| English et al. | Progress report from the testing program for stimulant and depressant drugs (1995) | |
| RU2652752C1 (ru) | Способ лечения бронхиальной астмы | |
| Somaini et al. | Clinical foundations for the use of methadone in patients with infectious diseases | |
| Nishikawa et al. | Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura | |
| Khotovitski et al. | P. 6.039 Efficacy of zuclopentixol treatmentof withdrawal syndrome in opiate dependent patients | |
| CN118416214A (zh) | 一种阻断单核巨噬细胞功能的cd38抑制剂在治疗itp中的应用 | |
| Ramirez Chan | Effect of Imipramine and Classical Benzodiazepines on Stress-induced Neuroimmune Dysregulation and Behavior |